Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Immunomedics, Inc.    IMMU

IMMUNOMEDICS, INC. (IMMU)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Immunomedics : Leaps Despite Q1 Loss

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 09:27pm CEST
Immunomedics, Inc. (NASDAQ: IMMU) shares spiked in Friday trading on first quarter numbers Total costs and expenses for the first quarter ended September 30, 2017 were $22.3 million, compared to $15.7 million for the same quarter in fiscal 2017, an increase of approximately 42%. Net loss attributable to stockholders was $118.7 million, or approximately $0.97 per share, for the first quarter ended September 30, 2017, compared to $16.2 million, or approximately $0.17 per share, for the same quarter in fiscal 2017, an increase of approximately 633%. Cash, cash equivalents, and marketable securities totaled $139.6 million as of September 30, 2017. Chairman Behzad Aghazadeh said, “During the quarter and over the course of the year, we have made significant progress toward preparing a BLA for accelerated approval of IMMU-132, our breakthrough therapy candidate for the treatment of late-stage metastatic triple-negative breast cancer (mTNBC). "IMMU-132 has shown a remarkable response rate in patients and we remain sharply focused on bringing this promising treatment to market as soon as possible. Notably, in the quarter, we completed a number of successful meetings with the (Food and Drug Administration) including a CMC and a pre-BLA meeting, where we received positive feedback on our proposed submission plans. As such, we remain on track to meet our stated goal of submitting our BLA filing in the first quarter.” Shares gained $2.03, or 19.4%, to $12.47.

Copyright © 2017 Baystreet.ca Media Corp. All rights reserved., source Standard Equities Feed

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on IMMUNOMEDICS, INC.
10:31aIMMUNOMEDICS : Priority Review for Immunomedics' ADC for TNBC
AQ
07/18IMMUNOMEDICS INC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
07/18FDA Accepts Biologics License Application for Filing and Grants Priority Revi..
GL
07/12IMMUNOMEDICS INC : Entry into a Material Definitive Agreement (form 8-K)
AQ
07/11Complimentary Technical Snapshots on Incyte and Three More Biotech Stocks
AC
06/27GLOBAL ANTIANDROGEN MONOTHERAPY MARK : The Global Antiandrogen Monotherapy Marke..
AQ
06/22IMMUNOMEDICS INC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
06/21TODAY'S RESEARCH REPORTS ON TRENDING : ACADIA Pharmaceuticals and Immunomedics
AC
06/15IMMUNOMEDICS INC : Entry into a Material Definitive Agreement, Other Events, Fin..
AQ
06/15Immunomedics Announces Closing of Public Offering of Common Stock
GL
More news
News from SeekingAlpha
07/18FDA accepts Immunomedics' BLA for sacituzumab govitecan for mTNBC; shares up .. 
07/10SECOND HALF OUTLOOK : What Now After Strong Double-Digit Gains? 
06/23What Does Breakthrough Therapy Designation Really Mean For My Company? 
06/21Daily Insider Ratings Round Up 6/19/18 
06/20A Short Case For A Longer Term! 
Financials ($)
Sales 2018 5,15 M
EBIT 2018 -128 M
Net income 2018 -203 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 881x
Capi. / Sales 2019 146x
Capitalization 4 540 M
Chart IMMUNOMEDICS, INC.
Duration : Period :
Immunomedics, Inc. Technical Analysis Chart | IMMU | US4529071080 | 4-Traders
Technical analysis trends IMMUNOMEDICS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 36,0 $
Spread / Average Target 40%
EPS Revisions
Managers
NameTitle
Michael Pehl President, Chief Executive Officer & Director
Behzad Aghazadeh Chairman
Michael R. Garone Chief Financial Officer & Vice President
Robert Iannone Chief Medical Officer, Head-Research & Development
Peter Barton Hutt Director
Sector and Competitors
1st jan.Capitalization (M$)
IMMUNOMEDICS, INC.58.97%4 540
CELLTRION, INC.--.--%32 830
IQVIA HOLDINGS INC12.03%22 488
LONZA GROUP9.38%21 400
INCYTE CORPORATION-25.70%14 887
SEATTLE GENETICS, INC.27.16%10 750